WuXi Biologics (Cayman)WXIBF 97 Net Current Asset Value is $0.40 as of Dec. 2025, which is 98% below its 10-year median of 23.31. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.12 (Fairly Valued). The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 77.39% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
WuXi Biologics (Cayman)'s net current asset value per share for the quarter that ended in Dec. 2025 was $0.40.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Net Current Asset Value or its related term are showing as below:
WXIBF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.04 Med: 23.31 Max: 60.71
Current: 12.22
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of WuXi Biologics (Cayman) was 60.71. The lowest was 8.04. And the median was 23.31.
WXIBF's Price-to-Net-Current-Asset-Value is ranked worse than 77.39% of 942
companies
in the Biotechnology industry
Industry Median: 4.88
vs WXIBF: 12.22
WuXi Biologics (Cayman) (OTCPK:WXIBF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
WuXi Biologics (Cayman) Net Current Asset Value Related Terms
WuXi Biologics (Cayman) Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) Net Current Asset Value Chart
WXIBF vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.40 mean?
WuXi Biologics (Cayman) (WXIBF) has a Net Current Asset Value of $0.40 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on WuXi Biologics (Cayman) and its competitors. This is 98% below median its historical median of 23.31. Over the past decade, WuXi Biologics (Cayman)'s Net Current Asset Value has ranged from 8.04 to 60.71. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #729 out of 942 companies in the Biotechnology industry, placing it in the top 77.4%.
Is WuXi Biologics (Cayman)'s Net Current Asset Value too high?
WuXi Biologics (Cayman)'s current Net Current Asset Value of $0.40 is 98% below median its 10-year median of 23.31. Over the past 10 years, this metric has ranged from a low of 8.04 to a high of 60.71. The Biotechnology industry median Net Current Asset Value is 4.88. WuXi Biologics (Cayman)'s value of $0.40 is 91.8% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #729 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #729 out of 942 companies for Net Current Asset Value. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Net Current Asset Value is 4.88. WuXi Biologics (Cayman)'s value of $0.40 is 91.8% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Net Current Asset Value has ranged from 8.04 to 60.71 over the past decade. While the company's 10-year median is 23.31 vs. the industry median of 4.88, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.88, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Net Current Asset Value of $0.40 is 91.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Net Current Asset Value is $0.40, which is 98% below median its own 10-year median of 23.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.12, compared to a current price of $4.77 — trading 6.9% below its estimated fair value. The current Net Current Asset Value is $0.40, which is 98% below median its 10-year median of 23.31 and 91.8% below the Biotechnology industry median of 4.88. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Net Current Asset Value is $0.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.77 is trading 6.9% below its estimated GF Value™ of $5.12.
GuruFocus considers WuXi Biologics (Cayman) to be Fairly Valued.
Key valuation signals for WXIBF:
Net Current Asset Value: $0.40 (98% below median its 10-year median of 23.31)
GF Value™: $5.12 vs. price of $4.77 (6.9% below fair value)
Industry Position: 91.8% below the Biotechnology median (#729 of 942)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
